| Vincent H Dodge, MD | |
|
12428 Whispering Oaks Dr, Baker, LA 70714-6027 | |
| (225) 775-7513 | |
| Not Available |
| Full Name | Vincent H Dodge |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 12428 Whispering Oaks Dr, Baker, Louisiana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497714919 | NPI | - | NPPES |
| 1216704 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD 200219 (Louisiana) | Secondary |
| 207P00000X | Emergency Medicine | ME158804 (Florida) | Primary |
| Entity Name | Southland Ems At Weems Pl |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124302443 PECOS PAC ID: 8820263171 Enrollment ID: O20111214000834 |
News Archive
Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.
Today's headlines spotlight the White House's push to defend the health law and advance positive messages about its benefits.
St. Jude Children's Research Hospital scientists have discovered how an important "on" switch is attached to the machinery that cells rely on to adapt thousands of proteins to meet changing conditions.
Melbourne researchers have discovered that the death of immune system cells is an important safeguard against the development of diseases such as type 1 diabetes, rheumatoid arthritis and lupus, which occur when the immune system attacks the body's own tissues.
According to a study published in the August issue of the Journal of the American College of Surgeons, there was an increase in the number of laparoscopic bariatric procedures, an increase in the number of bariatric surgeons and a decrease of inhospital mortality rates between 2003 and 2008.
› Verified 1 days ago
| Entity Name | App Of Florida Ed, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407338932 PECOS PAC ID: 7012252299 Enrollment ID: O20181217000426 |
News Archive
Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.
Today's headlines spotlight the White House's push to defend the health law and advance positive messages about its benefits.
St. Jude Children's Research Hospital scientists have discovered how an important "on" switch is attached to the machinery that cells rely on to adapt thousands of proteins to meet changing conditions.
Melbourne researchers have discovered that the death of immune system cells is an important safeguard against the development of diseases such as type 1 diabetes, rheumatoid arthritis and lupus, which occur when the immune system attacks the body's own tissues.
According to a study published in the August issue of the Journal of the American College of Surgeons, there was an increase in the number of laparoscopic bariatric procedures, an increase in the number of bariatric surgeons and a decrease of inhospital mortality rates between 2003 and 2008.
› Verified 1 days ago
| Entity Name | Santa Rosa Hb Medical Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982384988 PECOS PAC ID: 4284089335 Enrollment ID: O20231010004073 |
News Archive
Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.
Today's headlines spotlight the White House's push to defend the health law and advance positive messages about its benefits.
St. Jude Children's Research Hospital scientists have discovered how an important "on" switch is attached to the machinery that cells rely on to adapt thousands of proteins to meet changing conditions.
Melbourne researchers have discovered that the death of immune system cells is an important safeguard against the development of diseases such as type 1 diabetes, rheumatoid arthritis and lupus, which occur when the immune system attacks the body's own tissues.
According to a study published in the August issue of the Journal of the American College of Surgeons, there was an increase in the number of laparoscopic bariatric procedures, an increase in the number of bariatric surgeons and a decrease of inhospital mortality rates between 2003 and 2008.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Vincent H Dodge, MD 12428 Whispering Oaks Dr, Baker, LA 70714-6027 Ph: (225) 775-7513 | Vincent H Dodge, MD 12428 Whispering Oaks Dr, Baker, LA 70714-6027 Ph: (225) 775-7513 |
News Archive
Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.
Today's headlines spotlight the White House's push to defend the health law and advance positive messages about its benefits.
St. Jude Children's Research Hospital scientists have discovered how an important "on" switch is attached to the machinery that cells rely on to adapt thousands of proteins to meet changing conditions.
Melbourne researchers have discovered that the death of immune system cells is an important safeguard against the development of diseases such as type 1 diabetes, rheumatoid arthritis and lupus, which occur when the immune system attacks the body's own tissues.
According to a study published in the August issue of the Journal of the American College of Surgeons, there was an increase in the number of laparoscopic bariatric procedures, an increase in the number of bariatric surgeons and a decrease of inhospital mortality rates between 2003 and 2008.
› Verified 1 days ago